PegBio aims to bulk up its finances to deliver weight-loss drugs
The Chinese developer of anti-obesity and diabetes drugs has applied for a Hong Kong listing to fund its commercial plans, but will face strong competition Key Takeaways: The company’s core…
Recent Articles
RELATED ARTICLES
-
Innogen Pharma jostles for a slice of the weight-loss market
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG
-
No respite for RemeGen as problems and losses pile up
9995.HK 688331.SHG
